Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE VirtualScopics, Inc.
ROCHESTER, N.Y., June 19, 2014 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, today announced that shareholders have voted for and ratified all four proposals contained in the company's 2014 proxy statement. The outcome of yesterday's vote at the Annual Meeting of Shareholders is as follows:
Five members of VirtualScopics' senior management team made presentations reviewing the company's business and future outlook. The Annual Meeting of Shareholders was webcast live and a replay of the meeting and accompanying slide presentations can be found on the company's website, www.virtualscopics.com, under "investors" and "webcasts" or at http://www.investorcalendar.com/IC?CEPage.asp?ID=172786.
About VirtualScopics, Inc.
Virtual Scopics, Inc. (NASDAQ:VSCP) is a leading provider of clinical trial imaging solutions to accelerate drug and medical device development. For risk-averse, time-constrained Clinical Trial Study Teams, Medical Directors and Imaging Scientists who require quality imaging data delivered on-time, within budget and on a consistent basis, VirtualScopics' clinical trial imaging solutions are an inspired true-exception to commonly accepted services provided by other clinical trial imaging providers. Because of the scientific and operational flexibility and responsiveness they can offer, VirtualScopics' clinical trial imaging solutions deliver special performance advantages compared to other image service providers that offer common, every day clinical trial imaging services. For more information about VirtualScopics, Inc. please visit www.virtualscopics.com.
For More Information, Contact:
Donna N. Stein, APR, Fellow PRSA
Managing Partner, Donna Stein & Partners
©2012 PR Newswire. All Rights Reserved.